LexaGene Appoints Dr. Eleanor Kolossovski to Director of Product Marketing
April 01 2020 - 7:58AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the
“Company”), a biotechnology company that develops genetic analyzers
for rapid pathogen detection and other molecular markers, today
announced the appointment of Dr. Eleanor Kolossovski to the role of
Director of Product Marketing.
Dr. Kolossovski will help lead the development
and execution of LexaGene’s go-to-market strategy for the LX
Analyzer, as well as build brand awareness and thought leadership
to propel significant growth opportunities in clinical diagnostics,
veterinary diagnostics, food safety testing, and other applied
market segments. This is the second key hire LexaGene has recently
announced, as the Company gears up for commercial manufacturing and
launch.
Dr. Jack Regan, CEO and Founder of LexaGene,
states, “LexaGene is at an exciting phase of our growth trajectory.
Our recent strategic hires and the talent we’ve attracted are a
testament to our unwavering commitment to building a world-class,
market-disrupting company. I’m delighted to have Eleanor join the
leadership team to help us successfully launch our automated,
on-site genetic analyzer to help with the ever-desperate need for
rapid gold standard diagnostics.”
Dr. Kolossovski is a seasoned product strategist
and marketer with a decade of experience in diagnostics and life
sciences. Over the years, she has held multiple sales and marketing
positions of increasing responsibility with companies in the
clinical diagnostics space such as BD (Becton, Dickinson and
Company), Roche, and Qiagen. She has a successful track record of
leading new product development from concept to launch, creating
and implementing effective marketing plans, and delivering
sustainable revenue and profitability growth across the
instruments, reagents, and services continuum. Most recently, she
was Senior Global Product Manager at Qiagen, where she led the
worldwide launch of kits for genetic analysis and a portable qPCR
cycler with a particular focus on the public health and applied
testing market segments. A molecular biologist by training, Dr.
Kolossovski received her PhD from the Australian National
University and completed an Executive MBA from the Australian
Graduate School of Management.
Daryl Rebeck, LexaGene’s President and
Co-founder, comments, “The strong expertise of the leadership team
with proven track records of bringing innovative technologies to
market will guide the Company through this last phase prior to
commercial launch. We are building what the market needs.
Multiplexed diagnostics like LexaGene’s analyzer, where healthcare
providers can test for multiple pathogens and get answers on what
is causing symptoms, are particularly useful for COVID-19 testing.
On the other hand, singleplex rapid tests that are only looking for
one virus can frustrate healthcare providers who may question
whether the test returned a false negative result or if the patient
is sick with something they hadn’t tested for such as the flu.”
LexaGene management discusses the current news
in this interview here.
About LexaGene Holdings
Inc.LexaGene is a biotechnology company that develops
genetic analyzers for pathogen detection and other molecular
markers for on-site rapid testing in veterinary diagnostics, food
safety and for use in open-access markets such as clinical
research, agricultural testing and biodefense. End-users simply
need to collect a sample, load it onto the instrument with a sample
preparation cartridge, enter sample ID and press ‘go’. The LX
Analyzer delivers excellent sensitivity, specificity, and breadth
of detection and can return results in about 1 hour. The unique
open-access feature is designed for custom testing so that
end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
Media Contacts Nicole Ridgedale Director of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor Relations Jay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024